Factors influenceing the release of 5-hydroxytryptamie from the rabbit intestine into the venous blood.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M K PAASONEN.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The Rauwolfia alkaloid raunescine (5 mg./kg., intraperitoneally) increased the concentration of 5-hydroxytryptamine in the brains of rats after iproniazid pre-treatment. This was evident 3 to 4 hr. after raunescine administration. There was no general increase in the noradrenaline content of the brains. In the intestine, raunescine depleted the 5-hydroxytryptamine content by about 50% within 3 to 4 hr. if the animals had been pre-treated with iproniazid. Iproniazid did not increase the content of noradrenaline in the intestine.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Some behavioural effects of raunescine and isoraunescine on pigeons have been studied; no qualitative difference was detected between their effects and those of reserpine. Isoraunescine is between five and ten times less potent than raunescine, which, in turn, is much less potent than reserpine in producing these effects.Both raunescine (5 mg./kg.) and isoraunescine (50 mg./kg.) were found to cause a reduction in the concentration of noradrenaline in the brains of rats. Raunescine (5 mg./kg.) also caused a reduction in the concentration of 5-hydroxytryptamine in brain; isoraunescine did not do so in the same dose; higher dose levels were not studied.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.